In a boost to Rituxan franchise, Roche nabs quick approval for polatuzumab vedotin
Roche’s latest antibody-drug conjugate has crossed the FDA finish line, gaining an accelerated approval a full two months ahead of schedule.
Polivy, or polatuzumab …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
